Marking a major leadership transition, Biocon Limited has appointed Shreehas Tambe as Chief Executive Officer and Managing Director, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board. As the first CEO of Biocon Limited, he will lead the combined platform across biosimilars and generics, strengthening the company’s ability to scale and compete globally. Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited.
This transition follows the full integration of Biocon Biologics Limited as a wholly owned subsidiary, creating a simplified and unified corporate structure. The strengthened organisation is positioned to lead in diabetes, obesity, oncology, and immunology through a diversified portfolio that includes biosimilars, insulins, complex generics, and peptides, including GLP–1 therapies.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said: “Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise. Shreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint.”
“Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with an estimated valuation of approximately USD 5.5 billion. As the first CEO to lead the combined business, Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare. I am confident he will drive disciplined execution and translate our scale into sustained global leadership.”
Speaking on Siddharth Mittal’s contributions, Ms. Mazumdar-Shaw added: “I would like to thank Siddharth for his tremendous contributions to Biocon. Since joining in 2013, he has served with distinction as Chief Financial Officer and later as CEO & Managing Director, playing a pivotal role in shaping the company’s growth trajectory. He will now transition to another leadership role within the Biocon Group.”
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said: “It is an honor and privilege to lead Biocon at such a pivotal moment, as we bring together our biologics and generics businesses to build a leading global medicines company. Biocon is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology. Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs.”
“As we expand our portfolio and global presence, my focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth. I am deeply grateful to our visionary Chairperson Kiran Mazumdar-Shaw and the Board of Directors for the trust and confidence placed in me and look forward to building on Biocon’s strong legacy to make a meaningful difference for patients worldwide.”
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream LinkedIn | The Mainstream Facebook | The Mainstream Youtube | The Mainstream Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.
